<DOC>
	<DOCNO>NCT02781818</DOCNO>
	<brief_summary>Purpose : To evaluate effectiveness intralesional triamcinolone treatment hidradenitis suppurativa Participants : Patients diagnose Hidradenitis Suppurativa active inflammatory HS lesion . Up 60 lesion treat . Between 20 60 patient enrolled dependent number lesion treat . ( 3 per patient ) Procedures ( method ) : Injection triamcinolone placebo active lesion hidradenitis suppurativa</brief_summary>
	<brief_title>A Randomized Controlled Trial Evaluating Efficacy Intralesional Triamcinolone Hidradenitis Suppurativa .</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled trial two concentration intralesional triamcinolone , triamcinolone 40mg/mL triamcinolone 10mg/mL , normal saline placebo control . For subject lesion deem appropriate study , one three treatment site mark sequential lettering skin marker document body location . Baseline pain level lesion record . At time lesion randomize 1:1:1 fashion treat intralesional triamcinolone 10mg/mL , triamcinolone 40mg/mL , normal saline placebo . Following treatment , subject give paper questionnaire ask rate level pain 1-10 scale lesion , whether believe target lesion resolve day 1 , 2 , 3 , 5 , 7 , 10 , 14 . On day 14 also rate helpful think treatment scale 0-4 . These patient-reported outcome without physician assessment felt clinically relevant outcome . Aim 1 . Characterize compare 3 regimen term day resolution treat lesion . Hypotheses Aim 1 : Days resolution treat lesion few treatment group compare normal saline placebo , few triamcinolone 40mg/mL compare triamcinolone 10mg/mL . Aim 2 . Characterize compare 3 regimen term pain level day 5 . Hypotheses Aim 2 : Rating pain le treatment group compare normal saline placebo , less triamcinolone 40mg/mL compare triamcinolone 10mg/mL day 5 . Aim 3 . Characterize compare 3 regimen term patient rating `` benefit treatment Hypotheses Aim 1 : Patient rating favorable treatment group compare normal saline placebo , favorable triamcinolone 40mg/mL compare triamcinolone 10mg/mL .</detailed_description>
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>1 . Male female &gt; = 16 year age 2 . Diagnosis history clinical feature consistent hidradenitis suppurativa &gt; 1 year 3 . Patient must inflammatory lesion time treatment . This inflammatory nodule define tender , palpable subcutaneous nodule , abscess define fluctuant , painful , subcutaneous nodule . Lesions great 2 centimeter size exclude . Inflammatory nodules abscess treat associated sinus tract , chronic HS lesion define tunneled lesion multiple opening surface skin . Sinus tracts without associate nodule abscess treatment target . 4 . Patient must antibiotics stable course oral antibiotic &gt; 4 week prior baseline visit . Allowable antibiotic treatment course topical clindamycin , topical chlorhexidine gluconate , oral doxycycline , oral minocycline , oral clindamycin +/ rifampin . 5 . Must able provide adequate inform consent 1 . Any patient sign active infection time screen related hidradenitis suppurativa 2 . Patients nonpermitted antibiotic 4 week prior baseline . Allowable antibiotic treatment course topical clindamycin , topical chlorhexidine gluconate , oral doxycycline , oral minocycline , oral clindamycin +/ rifampin . 3 . Patients surgical intervention treat body region ( i.e. , right axilla ) beyond incision drainage procedure last 8 week open surgical wound treatment region . 4 . Patients start immunomodulatory biologic treatment ( i.e. , adalimumab , infliximab ) past 4 week 5 . Patients nonstable dos opiate analgesic last 14 day prior screen 6 . Patients history hypersensitivity reaction triamcinolone 7 . Ongoing health physical exam concern investigator feel may put patient significant risk</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>hidradenitis</keyword>
	<keyword>intralesional</keyword>
	<keyword>triamcinolone</keyword>
</DOC>